Mouse/Rat Hybridoma based Antibody Discovery Service
Background Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
The Enduring Innovation and Impact of Hybridoma Technology
The mouse/rat hybridoma platform, based on Köhler and Milstein's 1975 technology, remains crucial for monoclonal antibody (mAb) development. It fuses antibody-producing B cells from immunized mice or rats with myeloma cells, generating hybridomas for specific, indefinite antibody secretion. Modern advancements in high-throughput screening, single-cell cloning, and immunization strategies have overcome traditional challenges like low fusion efficiency and clone instability, ensuring consistent production of high-quality, specific mAbs. This platform is vital for cutting-edge diagnostics, innovative therapeutics, and fundamental biological research globally.
Creative Biolabs' mouse/rat hybridoma platform delivers high-affinity, specific, and stable monoclonal antibodies. They offer customized solutions to significantly reduce project timelines and ensure reliable, reproducible antibody production. Creative Biolabs provides the precision tools necessary to advance scientific and therapeutic endeavors, aiming to meet stringent requirements for diagnostics, therapeutics, and fundamental research, enabling breakthroughs in diverse fields.
Request a Consultation Today! Our experts are ready to discuss your unique antibody needs and design a tailored solution.
Conventional Hybridoma Workflow
Hybridoma technology is characterized by an effective fusion of innate functions of both immune and cancer cells, allowing the generation of hybridoma cells, which continuously produce mAbs specific to a desired antigen.
I. Immunization;
II. Cell isolation and culture;
III. Somatic cell fusion;
IV. Separation and screening;
V. Multiplication.
Fig.1 Illustrating hybridoma antibody production.1,3
Publication
This publication introduces the neuroscience monoclonal antibody sequencing initiative (NeuroMabSeq), a collaborative effort aimed at determining and publicly sharing hybridoma-derived sequences of monoclonal antibodies (mAbs) critical for neuroscience research. The paper describes a novel high-throughput DNA sequencing workflow and an associated bioinformatics pipeline to obtain variable domain sequences from a large collection of validated mouse mAbs. This initiative seeks to overcome the limitations of traditional hybridoma maintenance by providing a permanent, molecularly defined archive of antibody sequences and enabling the efficient generation of recombinant mAbs (R-mAbs) and single-chain variable fragments (scFvs) with enhanced research utility. The developed NeuroMabSeq website and database serve as a public repository for these sequences, offering tools for analysis and facilitating the dissemination of these valuable research reagents.
Fig.2 Integrated sequencing and bioinformatics analysis.2, 3
Why Choose Us?
Creative Biolabs is a premier partner in antibody development, offering unparalleled advantages through its mouse/rat hybridoma platform:
-
Unrivaled expertise: Over two decades of experience handling diverse and challenging antigen types, minimizing project risk, and accelerating timelines.
-
Dual-species flexibility: Leverages both mouse and rat models for enhanced immunization strategies, providing unique epitope specificities and expanding antibody diversity, especially for difficult antigens.
-
Comprehensive workflow, seamless execution: End-to-end service from antigen preparation to antibody characterization, ensuring a smooth, efficient, and high-quality process with minimal client oversight.
-
Superior antibody quality: Stringent quality control guarantees high-affinity, high-specificity, low-endotoxin monoclonal antibodies suitable for sensitive research, diagnostic, and therapeutic applications.
-
Customized solutions: Highly adaptable platform offering bespoke solutions and flexible project designs to precisely meet unique scientific objectives, budget, and timelines, prioritizing client success.
FAQs
Q1: What is the typical success rate for generating a specific monoclonal antibody using your platform?
A1: While success rates can vary depending on antigen complexity and desired antibody characteristics, Creative Biolabs boasts a high success rate due to our optimized immunization protocols, advanced screening technologies, and rigorous cloning processes.
Q2: How do you handle intellectual property and confidentiality for custom antibody development projects?
A2: Creative Biolabs places the highest priority on intellectual property protection and confidentiality. All projects are conducted under strict confidentiality agreements (CDAs), and the intellectual property rights to the generated antibodies and hybridoma cell lines typically belong to the client.
Q3: Can your platform generate antibodies of specific isotypes or with particular functional properties, such as blocking activity?
A3: Our screening methodologies identify antibodies based on antigen binding and specific functional properties. We use high-throughput functional assays to select clones with precise characteristics, such as blocking, neutralizing, or a specific IgG subclass (e.g., IgG1, IgG2a).
Customer Review
-
Enhanced Assay Performance
The antibodies developed by Creative Biolabs using their hybridoma platform significantly enhanced the performance of our diagnostic ELISA assays. We observed a marked improvement in sensitivity and reduced background noise, which was critical for our low-abundance biomarker detection. - Dr. S***h K
-
Overcoming Immunogenicity Challenges
We had a particularly challenging antigen with low immunogenicity, but Creative Biolabs' mouse/rat hybridoma platform successfully generated a panel of high-affinity antibodies. Their expertise in immunization strategies for difficult targets truly made the difference, allowing us to proceed with our structural biology studies. - Prof. L***n W
Related Services
To further support your research and development goals, Creative Biolabs offers a suite of complementary services that can seamlessly integrate with our mouse/rat hybridoma platform, providing a comprehensive solution for your antibody needs:
Biological Activity Testing Service
Antibody-directed enzyme prodrug therapy (ADEPT) is a specific cancer treatment. Creative Biolabs offers precise ADEPT in vitro testing services, including bioactivity assays, to support client research and product development with high specificity and minimal side effects.
Learn More →
High Content Screening Services
Creative Biolabs utilizes innovative high content screening services (HCS) technology to create customized assays for rigorous research. Combining expertise in bioinformatics, disease biology, and image analysis, they provide robust, scalable HCS services globally.
Learn More →
Contact Us
Creative Biolabs is an outstanding global service provider across a wide range of biotech fields, and our hybridoma team is equipped with technical expertise, high-end facilities, and top-ranking conditions. We have developed a versatile Hybridoma Platform, a high-throughput hybridoma generation and screening technology based on novel ClonePix systems, which can provide one-stop, customized mouse/rat hybridoma services for many applications, such as drug development.
If there is any query regarding our services or quotes, please contact us for more information.
References
-
Saeed, Abdullah FUH, et al. "Antibody engineering for pursuing a healthier future." Frontiers in microbiology 8 (2017): 256891. DOI: https://doi.org/10.3389/fmicb.2017.00495
-
Mitchell, Keith G., et al. "High-volume hybridoma sequencing on the NeuroMabSeq platform enables efficient generation of recombinant monoclonal antibodies and scFvs for neuroscience research." Scientific Reports 13.1 (2023): 16200. DOI: https://doi.org/10.1038/s41598-023-43233-4
-
Distributed under Open Access license CC BY 4.0, without modification.
